MMP9 and type 2 diabetes mellitus: In addition, a clinical study showed that the combination of VNN1 and matrix metallopeptidase 9 (MMP9) may be used as a novel blood biomarker panel to discriminate between pancreatic cancer-associated diabetes and type 2 diabetes [13].